NDAORALTABLET
Approved
Feb 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
5/8 — Partial
ANTIVERT (meclizine hydrochloride) by R-Pharm US is h1 receptor. Approved for vertigo associated with diseases affecting the vestibular system in adults. First approved in 1957.
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ANTIVERT (meclizine hydrochloride) is an oral H1 receptor antagonist approved in 1957 for treating vertigo associated with vestibular system diseases in adults. The drug works by blocking histamine H1 receptors, reducing inner ear stimulation and alleviating dizziness symptoms. It is a first-generation antihistamine with established efficacy in vestibular disorders.
$0.002BPart D
LOE ApproachingProduct is in late-stage lifecycle with minimal Part D spending, indicating a mature market with limited growth opportunities and likely smaller commercial teams.
Mechanism of Action
H1 receptor.
Career Relevance
Working on ANTIVERT offers limited career growth and mobility due to its LOE status, minimal spending, and mature market positioning. Roles are primarily defensive and maintenance-focused, suited for early-career professionals seeking stability rather than high-growth trajectory.
Brand Manager
Worked on ANTIVERT at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.